Patents by Inventor Bret A. Coldren
Bret A. Coldren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11859180Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: GrantFiled: June 9, 2020Date of Patent: January 2, 2024Assignee: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20210079391Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: June 9, 2020Publication date: March 18, 2021Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20190316123Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: November 28, 2018Publication date: October 17, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Patent number: 10174318Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: GrantFiled: October 14, 2016Date of Patent: January 8, 2019Assignee: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Publication number: 20170211062Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: October 14, 2016Publication date: July 27, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Patent number: 9616126Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.Type: GrantFiled: October 29, 2015Date of Patent: April 11, 2017Assignee: Grifols Therapeutics, Inc.Inventors: Jianxin Guo, Anthony Klos, Bret Coldren, Deborah Barnette, Mark Manning
-
Publication number: 20160106843Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.Type: ApplicationFiled: October 29, 2015Publication date: April 21, 2016Applicant: Grifols Therapeutics Inc.Inventors: Jianxin Guo, Anthony Klos, Bret Coldren, Deborah Barnette, Mark Manning
-
Patent number: 9301874Abstract: Lacrimal inserts such as punctal plugs may be utilized for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured for controlled, pulsatile release into the eye.Type: GrantFiled: March 1, 2012Date of Patent: April 5, 2016Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Bret A. Coldren, Peter Paul Willem Leonard Van Den Bekerom, Antonius Wilhelmus Maria De Laat, Johannes Wilhelmus Weekamp, Victor Lust, Gerald Yewey
-
Publication number: 20160002624Abstract: The present disclosure provides compositions comprising an antisense oligonucleotide and one or more excipients that modulates viscosity, turbidity or both viscosity and turbidity. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity are provided. In certain embodiments, compositions comprising an antisense oligonucleotide and one or more excipients having low turbidity are provided. In certain embodiments, pharmaceutical compositions comprising an antisense oligonucleotide and one or more excipients having low viscosity and turbidity are provided.Type: ApplicationFiled: May 17, 2013Publication date: January 7, 2016Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Andrew Dibble, Lloyd Tillman, Bret Coldren, Marc Lim
-
Patent number: 9125715Abstract: This invention discloses methods and apparatus for providing pulsatile release of active agents via a punctal plug inserted into a punctum. A tube is provided which may be inserted into a cavity of a punctal plug. One or more pulsatile delivery units are arranged in a generally linear fashion within the tube. The pulsatile delivery units include a core comprising the active agent and an encapsulation layer around the core.Type: GrantFiled: May 8, 2013Date of Patent: September 8, 2015Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Randall B. Pugh, Jason M. Tokarski, Bret A. Coldren
-
Patent number: 8894602Abstract: Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid and includes means for directional release of medication into the lacrimal fluid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye.Type: GrantFiled: August 2, 2011Date of Patent: November 25, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventor: Bret A. Coldren
-
Patent number: 8821457Abstract: Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye and is configured for release medication via a designated port, valve, or orifice in the insert housing and inhibits diffusion of medication via the housing itself.Type: GrantFiled: August 3, 2011Date of Patent: September 2, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Nathan R. F. Beeley, Bret A. Coldren, Victor Lust
-
Patent number: 8808256Abstract: A punctal plug or lacrimal insert comprising a microelectromechanical system pump and associated reservoir may be utilized to deliver precise dosages of an active agent into the eye though the tear film. The microelectromechanical system pump comprises four main components; namely, a reservoir, a pump, a series of valves and a vent. The microelectromechanical system pump is positioned within a cavity in the punctal plug. The microelectromechanical system pump is positioned with a cavity in the punctal plug.Type: GrantFiled: January 16, 2012Date of Patent: August 19, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Stephen R. Beaton, Michael Ferran, Justin Scott Jacobs, Jason M. Tokarski, Christopher S. Gudeman, Fardad Chamran, Paul J. Rubel, Bret A. Coldren
-
Patent number: 8808257Abstract: This invention discloses methods and apparatus for providing pulsatile release of active agents via a punctal plug inserted into a punctum. A tube is provided which may be inserted into a cavity of a punctal plug. One or more pulsatile delivery units are arranged in a generally linear fashion within the tube. The pulsatile delivery units include a core comprising the active agent and an encapsulation layer around the core.Type: GrantFiled: August 17, 2010Date of Patent: August 19, 2014Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Randall B. Pugh, Jason M. Tokarski, Bret A. Coldren
-
Publication number: 20130184661Abstract: A punctal plug or lacrimal insert comprising a microelectromechanical system pump and associated reservoir may be utilized to deliver precise dosages of an active agent into the eye though the tear film. The microelectromechanical system pump comprises four main components; namely, a reservoir, a pump, a series of valves and a vent. The microelectromechanical system pump is positioned within a cavity in the punctal plug. The microelectromechanical system pump is positioned with a cavity in the punctal plug.Type: ApplicationFiled: January 16, 2012Publication date: July 18, 2013Inventors: Stephen R. Beaton, Michael Ferran, Justin Scott Jacobs, Jason M. Tokarski, Christopher S. Gudeman, Fardad Chamran, Paul J. Rubel, Bret A. Coldren
-
Publication number: 20130131192Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.Type: ApplicationFiled: November 2, 2010Publication date: May 23, 2013Inventors: Jianxin Guo, Anthony Klos, Bret Coldren, Deborah Barnette, Mark Manning
-
Patent number: 8377042Abstract: The invention provides devices useful for the delivery of active agents to the eye in a controlled manner. In the devices of the invention, the active agent is present within the device in a continuous or discontinuous concentration gradient.Type: GrantFiled: May 13, 2010Date of Patent: February 19, 2013Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Zhigang Li, Michael J. Trezza, II, Maureen J. Borgia, Aruna Nathan, Bret A. Coldren
-
Publication number: 20130018360Abstract: This invention relates to a method of delivering ophthalmic drugs, specifically prostaglandins and prostamides. This method may also be applied to other types of intraocular pressure (IOP)-lowering drugs (e.g. carbonic anhydrase inhibitors, beta blockers, alpha-adrenergic agonists, and parasympathomimetics) as well as other types of ophthalmic drugs for other indications (e.g. dry eye, inflammation, and infection).Type: ApplicationFiled: June 22, 2012Publication date: January 17, 2013Inventors: Marissa Dockendorf, Günter Solms, Bailin Laing, Bret A. Coldren, Gary Yewey, Gerald Yewey
-
Publication number: 20120283669Abstract: Lacrimal inserts such as punctal plugs may be utilized for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured for controlled, pulsatile release into the eye.Type: ApplicationFiled: March 1, 2012Publication date: November 8, 2012Inventors: Bret A. Coldren, Peter Paul Willem Leonard Van Den Bekerom, Antonius Wilhelmus Maria De Laat, Johannes Wilhelmus Weekamp, Victor Lust, Gerald Yewey
-
Publication number: 20120197217Abstract: Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid and includes means for directional release of medication into the lacrimal fluid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye.Type: ApplicationFiled: August 2, 2011Publication date: August 2, 2012Inventor: Bret A. Coldren